Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 4Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Lymphoma 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Squamous Cell 2Brain Neoplasms 2Adenocarcinoma 2Urticaria 1Tuberous Sclerosis 1Thrombosis 1Squamous Cell Carcinoma of Head and Neck 1Smoking 1Small Cell Lung Carcinoma 1Severe Combined Immunodeficiency 1Sarcoma 1Salivary Gland Neoplasms 1Renal Insufficiency, Chronic 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Dysautonomias 1Polycythemia Vera 1Polycythemia 1Polycystic Ovary Syndrome 1Pancreatitis, Chronic 1Pancreatitis 1Pancreatic Cyst 1Ovarian Neoplasms 1

Interventions

Radiotherapy 6Doxorubicin 5Nivolumab 4pembrolizumab 3Sunitinib 3Ifosfamide 3Gemcitabine 3Docetaxel 3pazopanib 2Radiation Dose Hypofractionation 2Radiation 2Methotrexate 2Ipilimumab 2Cisplatin 2CTLA-4 Antigen 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1toripalimab 1temsirolimus 1spartalizumab 1sintilimab 1ribociclib 1regorafenib 1pegfilgrastim 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1itacitinib 1fludarabine 1eribulin 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Histiocytoma, Malignant Fibrous × Phlebotomy × Clear all
NCT03946943 2019-07-10

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

The First Hospital of Jilin University

Phase 2 Unknown
25 enrolled
Sarcoma

Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡